A blood protein called MMP12 could help predict pancreatic cancer up to 8 years before diagnosis. A European case-control study found that higher MMP12 levels were linked to a significantly increased cancer risk — strongest in patients diagnosed within 4 years of blood collection. Researchers say it shows promise as an early inflammatory biomarker for one of cancer's hardest-to-catch diseases.
Pancreatic cancer is notoriously difficult to catch early, but a new study suggests a common immune protein could serve as an early warning signal. Researchers found that elevated blood levels of MMP12 — a protein involved in immune and inflammatory processes — were significantly associated with an increased risk of developing pancreatic cancer, even years before a formal diagnosis.
The nested case-control study, published in the International Journal of Cancer, analyzed 92 immune proteins in blood samples from 406 pancreatic cancer patients across 10 European countries, matched against 406 healthy controls. After adjusting for smoking, alcohol use, diabetes, and BMI, MMP12 was the only protein that remained independently and significantly linked to cancer risk in multivariable analysis.
By the Numbers:
Why it matters: Pancreatic cancer has one of the lowest survival rates of any cancer, largely because it's rarely caught early. If MMP12 can reliably signal cancer risk years in advance, it could open the door to earlier screening and intervention — potentially saving lives.
